Lanthanum Carbonate

Quick links

Choose a section

Quick links to important sections

Advertisements

Lanthanum Carbonate

Selected form

Advertisements
Advertisements

Overview of Lanthanum Carbonate

Property Description
Active Ingredient Lanthanum Carbonate (Lanthanum(III) carbonate)
Form Chewable tablet, Oral powder
Pharmacological Class Phosphate Binder / Phosphate-Reducing Agent
General Purpose To reduce the absorption of phosphate from food
Origin Synthetic (inorganic carbonate salt)

What Type of Medicine is Lanthanum Carbonate?

Lanthanum Carbonate is a prescription-only pharmaceutical agent strictly classified as a Phosphate Binder (Phosphate-Reducing Agent). Its core purpose is to help maintain a healthy balance of serum phosphate levels in the body by reducing the absorption of phosphate from consumed food. This medication is one of the non-calcium, non-aluminum phosphate binders.

The classification as a Phosphate Binder defines its precise role as a compound that chemically sequesters dietary phosphate. This action is critical for individuals experiencing hyperphosphatemia (elevated phosphate levels), a typical scenario being in patients with compromised kidney function. The drug's efficacy in managing these levels is clinically recognized for minimizing the complications associated with mineral imbalance.


Lanthanum Carbonate: Composition and Dosage Forms

The active substance is Lanthanum Carbonate, which is a synthetic, single-ingredient product derived from the rare earth element Lanthanum. It is an oral formulation available primarily as a chewable tablet and an oral powder. Both dosage forms are designed for the oral route of administration to ensure the active component is delivered directly to the gastrointestinal tract.

The chemical structure, as a carbonate salt, allows the medicine to readily dissociate in the acidic environment of the stomach to release lanthanum ions. Its function is entirely localized to the digestive system, as it exhibits minimal absorption into the systemic circulation.


How Does Lanthanum Carbonate Function as a Phosphate Scavenger?

Lanthanum Carbonate functions as a highly effective phosphate scavenger by leveraging the chemical properties of its active ion. Once released in the gut, the lanthanum ions bind strongly to the dietary phosphate molecules, forming a stable, insoluble lanthanum-phosphate complex. Since the body cannot break down or absorb this compound, the complex is safely and naturally eliminated through the stool, thereby ensuring successful inhibition of phosphate absorption into the circulation.

Advertisements

What side effects are possible with Lanthanum Carbonate?

Possible Side Effects and Safety Information

The safety profile of Lanthanum Carbonate is primarily characterized by gastrointestinal adverse reactions.

Common Side Effects

Adverse reactions that have been reported frequently include nausea, vomiting, diarrhea, and abdominal pain. These gastrointestinal events are the most common side effects reported and were the primary reason for discontinuation in clinical trials, though they may lessen with continued use. Headache is also a very commonly reported side effect.

Serious Adverse Reactions

Serious cases of gastrointestinal obstruction, ileus (bowel paralysis), intestinal perforation, and fecal impaction have been reported in post-marketing experience. Patients with a history of gastrointestinal surgery, altered anatomy, or motility disorders may be at higher risk. The risk of these serious events is associated with the tablet not being completely chewed or crushed before swallowing. Allergic skin reactions and tooth injury have also been reported in post-marketing use.

Safety Restrictions and Precautions

Contraindications: This medication is contraindicated in patients with known bowel obstruction, ileus, or fecal impaction.

Dosing Caution: The chewable tablets must be chewed or crushed completely before swallowing to reduce the risk of serious gastrointestinal adverse events. Intact tablets should not be swallowed.

Drug Interactions: Lanthanum Carbonate can significantly reduce the absorption of other oral medications. Dosing separation of several hours is typically required, particularly for drugs where reduced bioavailability is clinically significant, such as certain antibiotics (quinolones, tetracyclines) and thyroid hormones (levothyroxine).

Special Populations: Safety and efficacy have not been established in pediatric patients. Use during pregnancy is generally not recommended, and caution is advised during breastfeeding due to unknown systemic effects on the infant.

Advertisements

Overdose and Emergency Response

Lanthanum Carbonate Overdose and When to Seek Help

Official regulatory information describes overdose manifestations for Lanthanum Carbonate as primarily involving an exaggeration of documented gastrointestinal effects.

Documented Manifestations and Severe Outcomes

Classification Documented Signs and Outcomes
Overdose Presentations Headache, nausea, and vomiting are listed as potential clinical signs. Over-ingestion may also lead to or worsen hypophosphatemia (low phosphate levels).
Severe Outcomes Life-threatening gastrointestinal complications, including obstruction, ileus/subileus, fecal impaction, and perforation, are serious risks documented in regulatory warnings. These outcomes may necessitate hospitalization or surgery.
Antidote Status No specific antidote is known for Lanthanum Carbonate overdose.

Official Emergency Actions

Immediate medical attention is required in the event of suspected overdose. Authorities instruct that the Poison Control Helpline must be contacted immediately. Urgent action is critical, and emergency services must be called if the individual experiences seizures, trouble breathing, collapse, or cannot be awakened.

Management procedures are restricted to supportive therapy to address any clinical symptoms. Furthermore, official labeling notes that the safety and efficacy of the drug have not been established in pediatric patients and that patients with hepatic impairment should be monitored carefully.

Advertisements

Therapeutic Uses of Lanthanum Carbonate

Lanthanum Carbonate is commonly used for managing a complex systemic mineral imbalance caused by the retention of phosphate due to kidney function challenges. The medication is primarily used to help with hyperphosphatemia, a condition of persistently elevated phosphate levels in the blood, which is commonly seen in patients with severe, long-standing kidney disease, including those with End-Stage Renal Disease (ESRD). This medication is a phosphate binder applied to reduce serum phosphate in patients with ESRD.

The key therapeutic benefit plays a role in managing the long-term risks linked to high phosphate, such as the formation of mineral deposits in soft tissues and blood vessels (vascular calcification). This generally offers supportive relief that helps patients cope more steadily with their condition by assisting in supporting cardiovascular and bone stability over time. This drug is a relevant part of care for adult patients receiving hemodialysis or peritoneal dialysis.

Quick Fact: Relief for Mineral Imbalance
This medication is applied in addressing symptoms related to systemic imbalance, specifically the management of high serum phosphate levels that interfere with functional stability in advanced kidney disease.
Advertisements

Eligibility and Restrictions for Use

Lanthanum Carbonate is approved for use in adult patients (aged 18 and over) to manage elevated serum phosphate levels in End-Stage Renal Disease (ESRD) and Chronic Kidney Disease (CKD).


Contraindications and Absolute Exclusions

The medicine is contraindicated and must not be used in patients with known hypersensitivity to the drug or any of its ingredients. Absolute exclusions also include patients presenting with bowel obstruction, ileus, fecal impaction, or existing hypophosphatemia (low serum phosphate levels).


Age and Physiological Restrictions

Population Eligibility Status
Pediatric Patients (Under 18) Not Recommended. Safety and efficacy have not been established.
Pregnant or Breastfeeding Women Not Recommended. Non-lanthanum binders are generally advised.

Conditional Use and Monitoring

Restricted or Conditional Use is mandated for patients with a history of gastrointestinal surgery, colon cancer, or active inflammatory bowel diseases such as Crohn's disease or ulcerative colitis. These groups require careful monitoring, as safety has not been established and there is an increased risk of severe gastrointestinal complications. No specific dose adjustment is needed for older adults or patients with hepatic impairment, though monitoring is advised.

Advertisements

What should I know about interactions with other medicines?

The official interaction profile for Lanthanum Carbonate is defined by a non-systemic, pharmacokinetic mechanism known as Physico-Chemical Absorption Interference. As a polyvalent cation in the gastrointestinal tract, Lanthanum forms insoluble complexes that reduce the systemic exposure of co-administered oral medications. This action is consistent with the drug's minimal systemic absorption; regulatory documents confirm no systemic metabolic (CYP-mediated) or transporter-based interactions are documented.

Interaction Type Affected Substances
Reduced Oral Bioavailability Quinolone Antibiotics (e.g., Ciprofloxacin, Levofloxacin); Thyroid Hormone Replacement Therapy (e.g., Levothyroxine); Cationic Antacids (and compounds susceptible to similar binding).
Exposure Outcome Clinically significant decrease in plasma levels (e.g., Ciprofloxacin absorption officially reported to be reduced by approximately 50%).

To mitigate the risk of reduced drug exposure, official labeling enforces mandatory timing separation rules. The primary restriction is managing this Clinically Significant Pharmacokinetic Interaction. Quinolone Antibiotics must be administered at least one hour before or four hours after Lanthanum Carbonate. Thyroid Hormone Replacement Therapy and compounds binding to Cationic Antacids must be separated by at least two hours. For other clinically significant oral medications, administration must be separated by at least one hour before or three hours after Lanthanum Carbonate. Monitoring blood levels is recommended for concomitant drugs with a narrow therapeutic range.

Advertisements

Mechanism of Action

How Lanthanum Carbonate Works

Local Chemical Binding and Chelation

This mechanism is centered on the direct chemical interaction of lanthanum ions with dietary phosphate in the gastrointestinal tract. Upon ingestion, the drug releases lanthanum ions, which immediately bind to the phosphate ions (PO4^3-), a process known as chelation, forming a stable, insoluble lanthanum phosphate complex in the gut lumen.


Modulation of Phosphate Absorption

Because the newly formed lanthanum-phosphate complex is insoluble, it cannot be absorbed across the intestinal wall into the bloodstream. This peripheral mechanism blocks the absorption pathway, leading to the increased fecal elimination of phosphate. This targeted action directly results in a reduction in the net transfer of phosphate into the systemic circulation, which contributes to a lower overall concentration of phosphate in the blood plasma.

Advertisements

Dosage and Administration Information

Lanthanum carbonate is strictly an oral medication, available as chewable tablets (in strengths such as 500 mg, 750 mg, and 1000 mg as lanthanum) and a corresponding oral powder. The entire usage protocol is structured to ensure the active ingredient is present in the digestive system concurrent with food intake. Therefore, the total daily dose must be divided and administered with or immediately following every meal.

The initial adult daily dose is typically 1500 mg of lanthanum, which is split into the prescribed number of meals. The dose is then managed over time, being adjusted (titrated) based on the patient's continuously monitored serum phosphate levels. Titration is generally performed in increments of 750 mg/day every two to three weeks until the phosphate target is achieved, often leading to a maintenance range between 1500 mg and 3000 mg per day.

Proper administration requires specific preparation. Chewable tablets must be chewed or crushed completely before swallowing and should never be swallowed whole. The oral powder must be mixed with a small amount of soft food and consumed without delay, as it should not be stored after mixing or dissolved in liquid. If a dose is missed, the recommended procedure is to skip that dose and resume the schedule with the next planned meal; two doses must not be taken simultaneously. This medication is intended for long-term management.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Lanthanum Carbonate

Evidence for Use in Hyperphosphatemia in Dialysis Patients

Research on Lanthanum Carbonate was evaluated for use in adult patients with End-Stage Renal Disease (ESRD) who are receiving dialysis. This includes individuals undergoing either hemodialysis or peritoneal dialysis. Structured research includes Randomized Controlled Trials (RCTs), where the medicine was evaluated in specific patient groups over short periods, typically between 4 and 12 weeks. Additionally, studies have been observed in trials comparing the medicine against other treatments, such as calcium-based products. The summary will describe what outcomes, such as shifts in serum phosphate and calcium levels, were consistently measured in these research settings.

The key biochemical axes that studies monitored were primarily changes in the level of serum phosphate and the Calcium imes Phosphate (Ca imes P) product in the blood. Studies reported measurements showing shifts in these key biochemical markers in the observed populations. Comparative trials reported differing patterns observed in the studies when the medicine was evaluated against other non-calcium and calcium-based phosphate binders.

What remains uncertain is the long-term data regarding major patient-level outcomes. Evidence derived from settings with varying symptom burdens includes long-term observational database studies that tracked patient data for up to six years, but controlled RCTs designed to measure the impact on patient-centered outcomes like all-cause mortality and cardiovascular event rates are not fully established. For these specific long-term outcomes, findings were mixed across various meta-analyses, and the evidence is limited to observational data.


Evidence for Use in Chronic Kidney Disease (CKD) Stages 4 and 5 (Pre-dialysis)

This part will focus on the research conducted in adult patients with advanced CKD who have not yet initiated dialysis. Research in this group includes randomized, placebo-controlled trials that examined patients with CKD Stages 4 and 5. Studies monitored shifts in serum phosphate levels and related bone biomarkers, such as FGF-23 and Parathyroid Hormone (iPTH).

These dedicated pre-dialysis trials reported measurements showing shifts in serum phosphate levels and bone biomarkers. Research provides insight into short-term changes in this population. However, the overall research base is less extensive compared to the evidence for patients on maintenance dialysis, and the follow-up durations were limited in many of the initial trials.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Lanthanum Carbonate (FAQ)


Q: Does Lanthanum Carbonate stay in your body for a long time?

Most of the lanthanum from the medication is designed to pass out of the body through the stool. The small amount of lanthanum that may be absorbed into the bloodstream has been identified in tissues, mainly the bone. According to regulatory documentation, the estimated mean elimination half-life for this small fraction is reported to be about 3.4 years.


Q: Is it possible for Lanthanum Carbonate to cause dental problems?

Yes, official safety information notes that tooth injury has been reported in post-marketing experience with the medication. The official product information notes that the tablets must be crushed completely before swallowing.


Q: How quickly can someone expect their phosphate levels to respond to Lanthanum Carbonate?

Clinical studies have shown that the phosphate-binding action of the drug is rapid, as it works locally in the gut. Official trial data indicates that when the drug was discontinued in studies, serum phosphorus concentration rose rapidly. This suggests the action is maintained by consistent use with meals.


Q: Can Lanthanum Carbonate be crushed and mixed with food?

The chewable tablets must be completely chewed or crushed before swallowing. The oral powder formulation is explicitly designed to be mixed with a small amount of soft food and consumed immediately. This administration method supports the drug's mechanism of binding to phosphate in the gastrointestinal tract.


Q: How long does it take for the body to eliminate the Lanthanum from the drug?

The majority of the dose is not absorbed and is eliminated in the feces shortly after administration. For the small fraction that may be absorbed and stored in the body, the estimated mean half-life of elimination from the bone is reported to be approximately 3.4 years, according to pharmacokinetic data.


Q: Can taking Lanthanum Carbonate make me feel tired or drowsy?

Official labeling lists the most common adverse reactions as primarily gastrointestinal events and headache. Fatigue or drowsiness are not listed among the commonly reported side effects identified in the official product information.


Q: Is Lanthanum Carbonate known to cause headaches or migraines?

Headache is listed in regulatory documents among the frequently reported adverse reactions identified in clinical trials. However, the official product information does not specifically classify or mention migraines.


Q: Does Lanthanum Carbonate have any known effects on cholesterol levels?

While the drug is not primarily studied for cholesterol management, regulatory documents note that Lanthanum Carbonate has the potential to decrease the absorption of certain statin lipid regulators, which are medications used for managing cholesterol.


Q: What happens if I take Lanthanum Carbonate without food?

The medication is designed to work locally in the gut by binding to phosphate in the food you eat. Because of this peripheral mechanism, it is officially required to be taken with or immediately after meals. Taking the medicine without food may reduce the intended effectiveness of the phosphate-binding action.


Q: What are the symptoms of taking too much Lanthanum Carbonate?

Official documents state that because the drug acts only in the digestive tract, it was not acutely toxic in animal studies. In official documents, the management for overdosage is described as supportive therapy, which addresses symptoms as they occur.


Q: Is Lanthanum Carbonate a metal-free drug?

No, the active component is Lanthanum, which is a rare earth element that functions as a polyvalent cation (a metal ion) in the digestive system. It is classified as one of the non-calcium, non-aluminum phosphate binders.


Q: Can I take other medications at the same time as Lanthanum Carbonate?

No. Lanthanum Carbonate can significantly reduce the absorption of many other oral medications. Official labeling requires time separation between Lanthanum Carbonate and other drugs, such as quinolone antibiotics and thyroid hormones, to prevent absorption interference.


Q: Is there a special way to dispose of unused Lanthanum Carbonate?

Disposal of any unused medication or waste material must be carried out in accordance with local requirements. Official guidance often refers to local drug take-back programs or approved disposal facilities as appropriate options for pharmaceutical waste.


Q: Does Lanthanum Carbonate need to be refrigerated?

Official instructions specify that the medicine must be stored at Controlled Room Temperature, which is between 20 C and 25 C (68 F and 77 F). It is explicitly instructed to be kept in its original container, tightly closed, and protected from light, moisture, and freezing.


Q: Do any official documents mention research on Lanthanum Carbonate for uses other than kidney disease?

The drug is officially indicated only for the reduction of serum phosphate in adult patients with end-stage renal disease (ESRD). Primary clinical sections and indications in regulatory documents do not describe or list other approved uses for this medicine.


Q: Is there a generic version of Lanthanum Carbonate available?

Yes, regulatory records from the FDA confirm that an approved generic version of Lanthanum Carbonate chewable tablets is available for use.


Q: What does 'phosphate binder' mean in simple terms?

A phosphate binder is a medicine that acts like a sponge within the digestive tract to attach directly to phosphate from consumed food. This action creates a compound that the body cannot absorb, allowing the phosphate to pass out harmlessly in the stool, thereby limiting the amount of phosphate that enters the blood.

Advertisements

How should Lanthanum Carbonate be stored and disposed of?

Storage and Disposal Requirements

Lanthanum carbonate must be stored at Controlled Room Temperature, specifically between 20^circ to 25 C (68^circ to 77 F), with permitted excursions up to 30 C (86 F). The medicine must be kept from freezing.

Storage Condition Requirement
Container Rule Store in the original package and keep the container tightly closed.
Protection Protect from light and moisture.
Child Safety Keep out of the reach of children.
Oral Powder Do not store the powder for future use once mixed with food.

Disposal of any unused medicinal product or waste material must be carried out in accordance with local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lanthanum Carbonate found in:

A-Z Index: